

Multiple Myeloma Care

*Translating Evolving Practices to
Oncology Nurses in Community Settings*



Faculty

Patricia Mangan, MSN, CRNP

Nurse Practitioner, (Hematology/Oncology) Abramson Cancer Center

University of Pennsylvania

Philadelphia, PA

Faculty Disclosure

Patricia Mangan, MSN, CRNP discloses the following relevant financial information with ineligible companies:

- Speaker's Bureau: BMS, Janssen, Karyopharm

Planner Disclosures

Academy Staff

John JD Juchniewicz, MCIS, CHCP, FACEHP, Wendy Gloffke, PhD and Paul Minitier, MS
– No relevant financial relationships with any ineligible companies.

Clinical Reviewer

Oxana Megherea, PharmD, BCOP
– Dr. Megherea has no relevant financial relationships with any ineligible companies.

Commercial Support Disclosure

This activity is supported through an educational grant from Sanofi, Legend Biotech, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Off-Label Usage

This presentation includes mention of medications that are not currently indicated in relapsed/refractory multiple myeloma (RRMM).


Objectives

1. Review evolving treatment options in RRMM and clinical implications
2. Examine how academic and tertiary care centers have integrated new treatments into practice in the setting of RRMM
3. Identify the most common and the unique chronic adverse events associated with long-term treatment of multiple myeloma
4. Describe the core principles surrounding mitigating and managing chronic adverse events in patients being treated in the RRMM setting
5. Outline the expanding roles of nurses, advanced practice providers (APPS), and nurse navigators when patients are treated with newer options in the RRMM setting

Have A Question For the Presenters?

*View right- hand side
to submit a question*


Patients With Multiple Myeloma Are Living Longer Than Ever



≈60%
LIVE MORE THAN
5 YEARS
after their diagnosis¹

1. SEER Cancer Stat Facts: Myeloma. Accessed March 19, 2023. <https://seer.cancer.gov/statfacts/html/mulmy.html>.


FDA-Approved Therapy for Multiple Myeloma Since 2000



CAR, chimeric antigen receptor; HDAC, histone deacetylase; MM, multiple myeloma; SINE, selective inhibitor of nuclear transport

Cancer.gov website. Drug therapy for multiple myeloma.

Common Treatments for Multiple Myeloma^{1,2}



Supportive care is essential



- VTE prophylaxis
- Bone modifying agents
- Infection prevention
- Renal protection
- Health maintenance

dex, dexamethasone; VTE, venous thromboembolism

1. Faiman B, et al. *J Adv Pract Oncol.* 2016;7(suppl 1):17-29; 2. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma—v.4.2024.



NCCN Recommendations for Adjunctive Treatment

Infection

- IVIG for recurrent infections
- Pneumococcal and influenza vaccine
- PJP, herpes and antifungal prophylaxis for high-dose or long-term steroids and teclistamab
- Herpes zoster prophylaxis with proteasome inhibitors, transplant, monoclonal antibodies, bispecific T-cell engagers

Bone disease

- Bisphosphonates, denosumab
- Radiation therapy
- Orthopedic consultation
- Vertebroplasty or kyphoplasty
- Calcium and Vitamin D supplementation

Renal dysfunction

- Avoid aggravating factors: contrast, NSAIDs, dehydration
- Not a contraindication to HCT
- Monitor bisphosphonates closely

Coagulation/thrombosis

- Prophylactic anticoagulation with IMiDs

Hypercalcemia

- Hydration, steroids, furosemide
- Zoledronic acid preferred
- Denosumab, calcitonin

Hyperviscosity

- Plasmapheresis


Anemia

- Consider erythropoietin
- Transfusion
- Type and screen patients prior to daratumumab administration

Antigen Targets in Multiple Myeloma (MM)

BCMA¹⁻³

Activates signal transduction pathways, upregulates anti-apoptotic proteins, and induces the expression of immunosuppressive molecules to drive MM cell proliferation and survival



SLAMF7⁶

Highly expressed on MM cells
Has a role in interactions between MM and stromal cells, as well as MM growth and survival and regulation of the immune response

GPRC5D^{4,5}

G protein-coupled receptor family C group 5 member D (GPRC5D) primarily expressed on myeloma cells, and limited to the hair follicle of skin and hard keratinizing tissues



CD38^{7,8}

MM cells express high levels of CD38
Regulates migration and receptor-mediated adhesion and has ectoenzyme activity

SLAMF, signaling lymphocytic activation molecule family


1. D'Agostino M, et al. *Curr Hematol Malig Rep*. 2017;12(4):344-357; 2. Cho SF, et al. *Front Immunol*. 2018;9:1821; 3. Sanchez E, et al. *Br J Haematol*. 2012;158(6):727-738; 4. Mailankody S, et al. *N Engl J Med*. 2022;387:2296-1206; 5. Chari A, et al. *N Engl J Med*. 2022;387:2232-2244; 6. Tai YT, et al. *Blood*. 2008;112(4):1329-1337; 7. Malavasi F, et al. *Physiol Rev*. 2008;88:841-886; 8. Deaglio S, et al. *J Immunol*. 1998;160:395-402.

Bispecifics vs Conventional Monoclonal Antibodies



CAR T Cell and Bispecific Antibodies

Mechanism of Action¹



1. Holstein SA, et al. *J Clin Oncol.* 2023;41(27):4416-4429. Epub 2023 Jul 20.

FDA-approved T Cell-directed Therapies

Efficacy Data – Registrational Trials¹⁻³


Therapy	N	Median Previous Lines of Therapy, No. (range)	Triple Class Refractory, %	Penta-Drug Refractory, %	High-Risk, %	ORR, %	≥CR, %	PFS	DOR	OS
Ide-cel ⁸	128	6 (3-16)	84	26	35	73	33	Median 8.8 months	Median 10.7 months	Median 19.4 months
Cilta-cel ^{9,16,17}	97	6 (4-8)	88	42	24	98	82.5	Median 34.9 months	Median 33.9 months	63% at 3 years
Teclistamab ¹⁰	165	5 (2-14)	78	30	26	63	39.4	Median 11.3 months	Median 18.4 months	Median 18.3 months
Talquetamab	232	6 (2-20)	75 SC 85 IV	25 SC 35 IV	16	63-72	21-28	Not reported	Median 7.8 - 10.2 months	Not reported
Elranatamab	123	5 (2-22)	100	87	25	61	35	Not reached at median follow up of 14.7 months	Not reached at median follow up of 14.7 months	Not reached at median follow up of 14.7 months

The FDA has mandated a black box warning for all marketed CAR-T therapies, citing a potential risk of inducing malignant T-cell tumors.

CR, complete response; DOR, duration of response; ORR, overall response rate; OS, overall survival; PFS, progression-free survival

1. Holstein SA, et al. *J Clin Oncol.* 2023;41(27):4416-4429. Epub 2023 Jul 20; 2. Chari A, et al. *N Engl J Med.* 2022;387:2232-2244; 3. Lesokhin AM, et al. *Nat Med.* 2023;29(9):2259-2267.

Overview of CAR T Cell Therapy



Bridging Therapy Goals:

Disease Control and to Decrease Tumor Burden

Regimens

- Steroids (eg, dexamethasone)
- Previous treatment
- Selinnoxor/pomalidomide /dexamethasone
- D-PACE or D-ACE
- Salvage auto transplant
- Radiation

Indications

- Control disease/rapidly growing disease
- Bulky disease
- Symptomatic patient (pain)
- Major organ involvement or obstruction
- Expected delay in CAR T cell production

Regimen selection

- Prior therapies
- Regimen-related AEs
- Site(s) of disease
- Comorbidities
- Blood counts
- Simplicity of administration

Lymphodepletion

Lymphodepletion is necessary for expansion of CAR T cells:

- Lymphodepletion creates a “favorable” environment for CAR T cell expansion and survival *in vivo*
- Administered on D-5, D-4, D-3 before CAR T cells are infused on D + 0
 - Fludarabine 30 mg/m² IV daily and cyclophosphamide 300-500 mg/m² IV x 3 days.¹⁻³

Premedication and Prophylaxis Considerations¹

Cell infusion premedication:

Acetaminophen and diphenhydramine (**NO steroids**)

Infection prophylaxis:


- Antiviral
- Antifungal and fluoroquinolone during neutropenic period
- PJP prophylaxis

Seizure prophylaxis may be considered

PJP, pneumocystis jiroveci pneumonia

1. Raju NS, et al. *Lancet Haematol.* 2022;9(2):e143-e161

CAR T Adverse Events and Timelines^{1,2}



1. Brudno JN, et al. *Blood*. 2016;127:3321-3330; 2. Neelapu SS, et al. *Nat Rev Clin Oncol*. 2018; 15:47-62.

CAR T-Cell AEs Onset

Acute AEs¹

- Cytokine-release syndrome
- Immune effector cell–associated neurotoxicity syndrome
- Cytopenias
- Hemophagocytic lymphohistiocytosis/macrophage activation syndrome

**Typically managed by
CAR T Cell Center**

Delayed AEs^{2,3}

- B-cell aplasia/hypogammaglobulinemia
- Prolonged cytopenias
- Late infections
- Long-term neurologic events/movement and neurocognitive treatment-emergent AEs
- Transient cardiac AEs

**Typically managed by
primary oncology team**

CRS¹

Cause: Activation/expansion of CAR T cells
increases levels of cytokines
(IL-6, IL-15, INF- γ , GM-CSF, others)

Onset: variable; 1 to 5 days

Duration: 3 to 5 days

Risk: Variable up to 5% in \geq grade 3

- Disease burden
- Peak CAR T cell levels
- Pre-treatment and peak cytokine levels

Biochemical Findings:

- Organ-specific markers
 - Creatinine, blood urea nitrogen
 - Troponin
 - Aminotransferases (AST/ALT), bilirubin
- Cytokine panels not readily available for “real-time” clinical use
- Easy to measure surrogates: ferritin, C-reactive protein
 - Trend to monitor the tempo of CRS

**In the end, CRS is a clinical, rather than laboratory diagnosis
Cytokine levels do not influence grading or treatment**

Treatment of CRS: Tocilizumab

Description	Humanized anti-IL-6 receptor IgG1 _κ monoclonal antibody
Mechanism of action	Inhibits IL-6 mediated signaling by binding to both soluble and membrane-bound human IL-6 receptors
FDA Expanded Approval 8/30/17	For the treatment of CAR T cell-induced severe or life-threatening CRS in patients 2 years of age and older
Dose	<ul style="list-style-type: none">• Adults: 8 mg/kg once (max dose of 800 mg)• As frequent as every 8 hours, max of 4 doses total
Administration	Intravenous over 1 hour
Required doses	Ensure that 2 doses of tocilizumab are available prior to infusion of CAR T cells
Monitor	<ul style="list-style-type: none">• For 7 days at the certified healthcare facility following infusion for signs and symptoms of CRS• Monitor patients for signs or symptoms of CRS for 4 weeks after infusion and seek immediate medicate attention

CAR, chimeric antigen receptor

Neelapu SS, et al. *Nat Rev Clin Oncol*. 2018;15:47-62. Neelapu SS, et al. *Nat Rev Clin Oncol*. 2018;15:218.

Neurotoxicity Associated with CAR T Therapy¹⁻⁴

Cause: Mechanism of toxicity is not clear

- T cell vs cytokine mediated??
- CAR T cells are seen in the CSF

Onset: 5-7 days after infusion; later than CRS

Duration: 5-10 days

- Fully reversible except in cases of fatal cerebral edema

Risk:

- High disease burden
- High IL-6 on Day 1
- Pre-treatment and peak cytokine levels
- Early or high-grade CRS
- Peak CAR T-cell levels

Neuro assessments

Wide range of symptoms from headache to encephalopathy, seizures

- Decreased attentiveness, anxiety, tremors, somnolence, disorientation, aphasia, nonsensical/tangential speech
- Parkinson-like movement disorders

Treatment:

- No clear response to anti-cytokine therapy
- Use of steroids and anti-seizure medications

CAR, chimeric antigen receptor; CRS, cytokine release syndrome; CSF, cerebrospinal fluid; DIC, disseminated intravascular coagulation

1. Maude SL, et al. *N Engl J Med*. 2014;371(16):1507-1517; 2. Davila ML, et al. *Sci Transl Med*. 2014;6(224):224ra25; 3. Lee DW, et al. *Lancet*. 2015;385(9967):517-528; 4. Kochendorfer JN, et al. *J Clin Oncol*. 2015;33(6):540-549.

Medications Can Reduce Infection Risk

Type of Infection Risk	Medication Recommendation(s) for Healthcare Team Consideration ¹
Viral: HSV/VZV	Acyclovir prophylaxis
Bacterial: blood, pneumonia, and urinary tract infection	Consider prophylaxis with levofloxacin
PJP (P. jirovecii pneumonia)	Consider prophylaxis with trimethoprim-sulfamethoxazole
Fungal infections	Consider prophylaxis with fluconazole
COVID-19 and Influenza	Antiviral therapy if exposed or positive for covid per institution recommendations
IgG < 400 mg/dL (general infection risk)	Consider IVIg
ANC < 1000 cells/ μ L (general infection risk)	Consider GCSF 2 or 3 times/wk (or as frequently as needed) to maintain ANC > 1000 cells/ μ L and maintain treatment dose intensity

Some people receiving BCMA-targeting therapies have experienced infections that are less common like CMV, PJP, EBV and fungal infections

ANC, absolute neutrophil count; CMV, cytomegalovirus; EBV, Epstein-Barr virus; GCSF, granulocyte colony-stimulating factor; HSV, herpes simplex virus; VZV, varicella zoster virus.

1. Raje NS, et al. *Lancet Haematol.*2022;9(2):143–161.

Bispecific Treatment Timeline



Week 1: Step-up dosing to mitigate incidence and severity of CRS and neurotoxicity

- Allow 48 hours between doses to assess for emerging CRS or ICANS
- Observation recommended as inpatient during step-up dosing at a REMS certified facility
- Hold dose for evidence of CRS or ICANS or active infection
- Premedicate 1-3 hours prior to all step-up doses and first full dose, or if prior dose was associated with CRS or ICANS
- Recommended pre-medications: glucocorticoid steroid, antihistamine, and antipyretic
- **Week 2 and onward: requires coordination of care with the community team and facility**

Teclistamab Safety

	Any Grade	Grade 3 or 4
	no. of patients (%)	no. of patients (%)
Neutropenia	118 (71.5)	108 (65.5)
Anemia	90 (54.5)	62 (37.6)
Thrombocytopenia	70 (42.4)	37 (22.4)
Infections	132 (80.0)	91 (55.2)
Cytokine release syndrome	119 (72.1)	1 (0.6)
Diarrhea	56 (33.9)	6 (3.6)
COVID-19	48 (29.1)	35 (21.2)
ICANS	5 (3.03)	0

Teclistamab: CRS and ICANS Prevention and Management

- Step-up dosing: 0.06 mg/kg, 0.3 mg/kg, 1.5 mg/kg separated by at least 48 hours
- Hospitalization recommended but may not be essential with robust outpatient monitoring
- Dexamethasone (16 mg), acetaminophen, and diphenhydramine pre-medication before step-up and first full dose.
- Tocilizumab is preferred for CRS management, although tocilizumab is not mentioned in teclistamab's FDA prescribing information or REMS
- Dexamethasone is preferred for ICANS management

Infections and Hypogammaglobulinemia

- Teclistamab phase 2 (N = 165)^{1,2}
 - 80% developed infections, 55.2% grade 3-4
 - 74.5% developed hypogammaglobulinemia (IgG <500 mg/dL)
 - 12 deaths from COVID-19
 - 8 additional deaths from infections including one PML (JC virus)
 - 6 cases of pneumocystis pneumonia
- Talquetamab phase 2 (N = 232)³
 - ~40% developed infections, 7% grade 3-4
 - ~80% developed hypogammaglobulinemia
 - 1 fatal infection, and no COVID-19 deaths

Understanding of infection risk evolved during these studies, and many patients did not receive prophylaxis

IgG, immunoglobulin G; JC, human polyomavirus 2; PML, progressive multifocal leukoencephalopathy.

1. Moreau P, et al. *N Engl J Med.* 2022;387:495-505; 2. van de Donk N, et al. *J Clin Oncol.* 2023;41(November 16_suppl):8011; 3. Chari A, et al. *N Engl J Med.* 2022;387:2232-2244.

Infection Prophylaxis With Bispecifics *

- Herpes zoster prophylaxis (FDA prescribing information)¹
- Intravenous immune globulin
- Pneumocystis prophylaxis for teclistamab
- Evaluate for CMV reactivation with cytopenias or other suggestive clinical symptoms
- Consider reduction in frequency to Q2W after stable response is achieved²

* Will probably be the same for all anti-BCMA bispecific agents

Management of Oral AEs¹

Taste Changes

Dexamethasone oral solutions “swish and spit” have been tried but with no proven benefit yet. Sour citrus or candies before meals are also recommended.

Glossitis and Thrush

EARLY initiation of nystatin or mycelex is key to manage symptoms.

Dry Mouth

OTC dry mouth rinse, gel, spray are recommended. Consider saliva substitute. Advise patients to avoid hot beverages.

Dysphagia


Dietary modifications with small bites, eating upright, and sips with food can help manage symptoms.

- **Weight loss and anorexia** are associated with taste changes. **Nutritionist** involvement and dietary modifications are recommended to support patients. An appetite stimulant with Marinol, if indicated, can also be utilized.
- **Education and emotional support are key strategies to manage oral toxicities.**

OTC, over-the-counter

1. Catamero D, Purcell K, Ray C, et al. Presented at the 20th International Myeloma Society (IMS) Annual Meeting Nurse Symposium; September 27–30, 2023; Athens, Greece.

Management of Dermatological AEs¹



- Consider dose HOLD for other grade 3 dermatologic AEs
- Dermatology consults may be helpful as an early strategy
- **With experience, dermatologic AEs can be managed more easily vs oral AEs**
- These interventions were successful at reducing or resolving dermatologic AEs

Nail Changes (Associated with Talquetamab – GPRC5D)



Palmar Plantar Desquamation (Associated with Talquetamab – GPRC5D)



Comparison of Immunotherapy Approaches

	MoABs	CARs	BiTEs
Off-the-shelf	YES	No	Yes
Ease of administration	+++	+	+ to ++
Repeated dosing required	Yes	No	Yes
Dependent on patient T cell “fitness”	No	Yes	Yes
Adverse events	IRR	CRS, neuro	CRS, neuro
Adverse event duration	NA	~14-21 days	Ongoing
Durable clinical activity seen	Yes	Yes	Yes
Requires LD chemotherapy	NO	Yes	No

LD, lymphodepleting; IRR, infusion-related reaction; MoAB, monoclonal antibody

Conclusion

- Significant advances in the treatment of myeloma continue to improve survival
- Highly effective immunotherapies, including CAR T and bispecifics, recently FDA approved for RRMM are showing great promise and are now moving earlier in lines of therapy at relapse.
- Close monitoring and aggressive management of the unique adverse events associated with these T cell-directed therapies is essential
- Adaption of these agents in RR disease is successfully moving to the community setting. Nurses, in community and CAR T centers, are essential in the successful coordination, symptom management and patient/family education.
- Myeloma patients are “Survivors”